<SEC-DOCUMENT>0001193125-13-441040.txt : 20131114
<SEC-HEADER>0001193125-13-441040.hdr.sgml : 20131114
<ACCEPTANCE-DATETIME>20131114061033
ACCESSION NUMBER:		0001193125-13-441040
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20131114
FILED AS OF DATE:		20131114
DATE AS OF CHANGE:		20131114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		131216652

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d628690d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Novogen Limited</B> (Registrant)</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Bursill</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Andrew Bursill</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Secretary</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 14 November 2013</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>NOVOGEN LIMITED</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="4" ALIGN="right">


<IMG SRC="g628690tx_pg03.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NASDAQ: NVGN</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">14&nbsp;November 2013</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novogen Announces Important Discovery in Program to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Develop Drugs Against Genetic and Degenerative Disorders </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Novogen compounds currently undergoing screening against 30 genetic disorders </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>including Cystic Fibrosis and Huntington&#146;s Disease </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Limited (ASX:NRT, NASDAQ: NVGN) is engaged in a pilot program aimed at the breakthrough development of drugs to treat a wide range of genetic and
non-genetic degenerative diseases including muscular dystrophy, motor neurone disease, Huntington&#146;s Disease, cystic fibrosis and Alzheimer&#146;s Disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The program has returned positive findings, with a pilot drug proving to be highly cytotoxic against the initial screen: stem cells from a neuromuscular
dystrophy disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The program is being conducted in collaboration with Australian company, Genea Biocells, which has pioneered the isolation and in
vitro differentiation of stem cells from embryos with genetic disorders and now holds the world&#146;s largest bank of pluripotent human embryonic stem cells with over 100 lines covering some 30 different diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The program is based on the discovery that one of the Novogen drug families induces apoptosis in cancer stem cells in a highly potent manner, with the company
to date focusing that biological property on the development of anti-cancer drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen CEO, Dr Graham Kelly, said that the success of the cancer
program led Novogen scientists to speculate that the same compounds might be equally effective against abnormally-behaving stem cells associated with common degenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The more we work with cancer stem cells, the more we have come to suspect that the action of our drugs is not so much the fact that the stem cells are
cancerous, but that they are behaving abnormally. It was this suspicion that led us to this pilot study looking at their effect on abnormal stem cells responsible for causing degenerative diseases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This early data completely supports our hypothesis. This is an exciting discovery for the Company and one that considerably expands its commercial
scope. Our immediate focus will always be on the development of anti-cancer drugs, but this discovery cannot be ignored given the life-disrupting seriousness of many genetic and degenerative disorders.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9476 0344 - F: +61 (0)&nbsp;2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As a result of this discovery, we now are committing the necessary resources to take this program to its
next phase, which is to design and screen drugs against a wide range of stem cells associated with diseases such as cystic fibrosis, muscular dystrophy, Fragile X, Huntington&#146;s Disease and Alzheimer&#146;s Disease,&#148; he added. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Kelly said destroying the aberrant stem cells was an important first step toward eventually being able to successfully treat these kinds of conditions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Uli Schmidt, General Manager of Genea Biocells said, &#147;We made the effort to establish our stem cell technologies for this very reason - to use it
as a resource to screen drugs in the hope of developing therapies for genetic disorders,&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Being able to selectively modulate disease-affected
stem and progenitor cells is a highly interesting observation that will help us better understand and potentially design treatments for such disorders&#148; Schmidt added. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd is a public Australian
biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol &#145;NVGN&#146;). The Company is based in Sydney, Australia and is focused on the development of novel anti-cancer drugs
based on two proprietary drug technologies - the super-benzopyran chemical family and anti-tropomyosin drug technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Genea Biocells </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genea Biocells Pty Ltd develops unique human stem cell tools to advance research and drug discovery in areas of unmet medical need. Genea Biocells partners
with industry for custom-developed cell-based assay solutions in drug development and supplies application-ready, disease-affected and control differentiated cell types, including neurons and skeletal muscle. Genea Biocells is a subsidiary of
fertility group Genea, a public, unlisted company that has been operating IVF clinics in Australia since 1985. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g628690tx_pg04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pluripotent stem cells </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human pluripotent stem cells can be expanded indefinitely in the laboratory and have the potential to differentiate to all cell types found in the human body.
When derived from patients or embryos carrying genetic diseases they present an invaluable resource to study mechanisms causing disease and to test pharmacological properties of drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9476 0344 - F: +61 (0)&nbsp;2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact details </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dr Graham Kelly, Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">


<IMG SRC="g628690tx_pg05.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tel: 61 2 9476 0344</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax: 61 2 9476 0388</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mobile: (61)&nbsp;0429 854 390</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:
<U>graham.kelly@novogen.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Web: www.novogen.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150; ACN
063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0)&nbsp;2 9476 0344 - F: +61 (0)&nbsp;2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g628690tx_pg03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g628690tx_pg03.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4@#L`P$1``(1`0,1`?_$`-L``0`"`@(#`0$`````
M```````("0<*!08!`P0+`@$!``$$`P$!``````````````$%!@<(`@0)`PH0
M```&`0,"`P0$!0L2!P````$"`P0%!@<`$0@2"2$3%#$B%19!(Q<843)"-39A
M<8&QTC-3)&0X&?"AT5)BDD/35)34564WEU@*&M4F9I8Y69D1``$#`@0#!`4&
M!@L1``````$``@,1!"$Q!09!41)A(A,'<8&1,@C14B,S%!5"8H+2-!>ADD-C
M<Y/3E#55&/"QP7*B4\/C5"5%E18F-E:6_]H`#`,!``(1`Q$`/P#?>L=BA*C7
MIZV662:PU<K$-*6&?F'RI4&,5"0K%>2E9)XL;8J+5BQ;**J&'P*0HCKA))'#
M&Z:4AL36DDG(`"I)[`%VK*RNM1O8=/LF.DO9Y61QL&)<][@UK0.)<X@#M*T,
MLY=^?N!W3,F2K/@K,[#&6%)&V29<64A?%.+[`]BJ0R/Z*!=RTQ9*K*3+J9GF
MC8'[DJBYBHK.12(!2$`H:H:_YT;B?JLWW(]D6F->0P%C'$@8=1+FDU.=*X+U
M2VA\'?EM'MNS&Z+>2XU[P&>.]L\S&ND(JZC62!H%3TMH!W0*XU)Q87O@=U?J
M(8W*..`GCUD^Q'"6_P"IX_(N^J-^N3?/3^D1U_@H_P`U7*/@_P#);J#C8S]/
M$?:;C^56R5V..YE?>:M(R5B/D9:(ZQ<CL4R1K.G8&T+!U<+[BFRO#)Q,LE!5
M]G'1*4C3ICJC'PMT$RBDJR4,`J*G,;/?EAOA^[M,DBU!S3K$#N\*`=3#DX``
M"@/=-!AA7$U6D?Q,>1]GY5:O;:CMJ.1NUKMI90ES_"F;4])>XEU)&=YH)P+7
MXT(`OPUE!:M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HBUIO^HLYO*XRP]7>&./IDS:]9]9'G,IKL''0]@<)QSP[4\2H*?U
MC=7(\ZV,S]H&-'LW9=ME`$,,^<F[?N711HMHZE_>`]5#BV(8']N>[Z`Y;I?!
MYY5C<NYI=]ZK'U:5IKNB`$8.N'"I>.R%AP.76\'-A"TS"I%12Z"@`E-T^`>P
MG2&Q0V#V;`&M1'5I4YKU2#!&WI&1_8HO(>(`.N30"*G-2I&\0>3]KX8<E<7\
MDZ@"[H:/+>CNL`D8P$M^,IP4V-ZK2A`]U1PYB!%PS$P""4@V04`-R:NW9&YI
M=K[AAU*,G[/U=,C?G,=@X>S$<B`L8^;?E[IWF3LJ\V[?`"22(F)_&.5O>CD'
M'NO`K3-O4TU!(/Z9V/K[4\IT6GY)HDPUL-+OE:A;=5IMD<%&TG!3\>A)QCQ,
M0$>D56KDHF(.QB&W*8`,`AK>V">*Y@9<0.#H9&AS2,B"*@^Q>'&K:7?:)JEQ
MH^I,,>H6LSXI&G@]CBT^D5&!R(H1@5W#7U5/31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$6H=_U(W#):)L%"YYTQBLHQD&T)AS
M.A$O,6*S414<!C"Y*$$Y_(;',NM#.C%`J93F9"/O&,(Z^>>.V)+FWAW+;"IB
MI'*.PD]#O;W3Z6KT(^"KS,@MC=>7.HN#9.IUQ;$_A--!-'RJTTD;Q(<_,-%-
M6;Q(/1MUBX#S"C^``#QW_6UK#G4C@O1W%O=SZ\04#V;?@]NN;0.GI1=ZQ9BF
M^9XR=CW!V,(P96_Y7M493*RCY2BJ#-Q)J[/9R2!(#&1A:W%D6?O51V*DU;*&
M$0`-]5G;FB76X=9M](M?K)7@5X!N9<>0`J3V!6KO3=&G;.VS=[@U5[8[*V@>
M]Q)^:,@.+G&C6@8N<0!B5ODY!Y.89[26(N,_$FH4:PY6<5;&S6)2BX:P1</(
MQ$#`)(M%+A8598KHA%KI957BJ*">P`<JW0`)D`->CNS]DSW6F,M+1_1:V[&L
M#G@GJ(&)P]IX8T&2_.5YY_$%IFD;QGU;5[=T^J:E+)<.BB<UO@L<ZD;22,:@
M4&1(;U$8K#G].E6/^5V__P#$&H?Z%J[OU<WG^TQ?M7+"7]J?;W]5W?\`&1_(
MI(\3^ZQCWD[F5GA9]C&R8JGIV"DY2H2-@LD)-Q]FE(<H.Y&MH!&((*,I0L.1
M5VEYFY5B-U"E]\``U)U;9FHZ39.OGN;)$TBH`-:'\+T`TKV&N05Y[&\^=N;V
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M:S=T`)J&\HZADC`!R&*&D&O;!W%I>KSV-M:7$\+)"&O9&YP<VN!J`<PO;'9'
MF]LW=.V;/76:A:Q&XMVN<R25@<QU.^QP)P<UU6GM"QJ&%<Y='5]A.<1-OL)/
ML>R/N`?AV^6M4@;2W2#0:?>]7\#)^:KI_P"O=F='7]YV.?\`GH_SELO]@_B&
MCA6L9I[BW)6L3&/FM2@;+3L5M;W!2=<F8&IPK<SS*.0/@DXU82#=6=5;)1$<
M<2%,LB@Z`FY5R#K9'R2V!?6#GZGJ$#F:I.X1Q,<"'-:?><0<17`5I@T.YKSK
M^-GSUT:33F;8TR[8[0[6,W5[(QP+3TU\*$&M":@O+3B7>%3-1`S3F&Q\A<PW
M[-UL*LA)7Z94=1,8N<3FKE08AZ*HUM+\4"EB85)(%-@`#N3JJ;;G'6_VD:?!
MI]BRU@-86,`KE4YD^LDGUK\X&\MR7F[-QW>N7I/C7$Q=2M>EN3&`\F,#6#*H
M;6@6..C^Z'^O_9UWZ1\E:^*^J,G+!3YNO72F2*D/<Z9/1EHJ\RD(E4CYJ'=$
M>-#B)1`3MUC$\I9,?=50.<A@$IA`?E-;PW;7?:`70%I'1SJ*'VA=[3-0NM+O
MHKVS>8[F)[7M<,VN:06GU$`TRX'!;LG&'/5>Y+X.H68:]Y2`6:)*2>B"*=:M
M=MD:86%GKSDHF,H12+F$%2$$WBH@*:@;E.41UXU;3WZ9?R6CJ](-6D\6G(^G
M@>T%>I.QMUVN\]LVVO6Q;XDC`)6C\"9H`D;QP!Q;B:M+3Q6?-4U7<FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*C3EEW=K'A;/=PQ!
MB3%]0R##4`K2%LUJL%DE8_KNP%,O-PL8WBVJR1VT"15)LN<YNKUA%2>PFLB;
M>V0S5K$W=T^2-Y%0!08'+,$DD8\,PM4_,3XA[_:^YY]#T&VLY[6V=X;GR>(X
MND'OTZ'-:&M=W,>HES7&HP"CP'>^SE[V_'_&'AML(7"T;>/X0]!OJL#R[T_"
MLL]>.+/S58Y^*3=O"PTSV3_RJXK+?,7)_<*XHYVQVW@8O'5_Q*\JF79ZA5.3
M?S*68<)0+HREJ:,%7S=N^0?U&8(WD';8OF%<HHI$`!$XEUPM=&M-L:O#.P/E
MAF:8^I].Y(:4R`%'MJT<CZ5]]8\R-=\V]BZCIU(;;4[%S+ET4(?2XMFU;(.^
MYSNJ!Y9,0#1S!@*L*IY;KI.4$5T#%.@JD0Z!B["`IG*!B"`AX"`@/AK(=&T'
M3E6I^1:L.:0XAV=5[M<E"_A00`AA`0W('6`#[!`-]]]2T$4<X'P^K%1B<.)5
MIW#3D[9."7%^Q9:EH12]L^0N6D6>&,/.)PE9]2QID<M%Y+RP,P>+FEF<$N[(
MUCP(1L8KART(8!`5!'6/MQ:5%N'6OL\#@P1,Q<!7%Q[K.&)[SSR!'SELSY8[
MVN?*O9LNLZ@WQX=0N0V"W+NDN$+2)KC)U&@N9""!](X$$@1BN>/Z=*W^&_$^
M.\3;!MF@VPAO[?\`=OX:I[O+B0/<UMQ7I%?=S[/>5X?VJ8<#]U8']^_U:R=A
M?O2HW[+M`Q_D7!++&=2NT\A6G-^)E`D^A7)*43.C!+R,8M2X0AHQ[+BDV66]
M23T_G`H("4IMJ?J.PKVQLS=-D#Z`F@'$8TS.>-.VBK>W?B8TS6-9M]-OK'[-
M;32M8Z7Q:A@<>D.(+!W0XCJQ%&U(J10WK:L%;1*./)+EQQTXA5NO6[D=D^)Q
M?7;5-JUROR4M'3\D23FD(YS++,44*]$R[HITX]FHH)CD*38NV_4(`)14!9II
MMQJ^0ZE6KW2)R/LU/N,'%V6L6&*6!Q&S4%-,T9"+DF2VQ1.W=LUR'+N`&#?8
M0`0$-%*QQ/\`(S"U7SK0>,\]?(V.SEE"HV6^4/'RK.7/)V*I4\PDL<TV>H1Z
ML,W0C#%$#$7<I*GV]PIM*\$62;=<*I0:W,7&\V6"I]3K[-20G;+9I5C"040Q
M2$`.ZD9217;LFB(&,!>HYP`3"`!XB`:(JQ)+OA=K2,DW<8KRSK#P63H[1>3A
MJ9E"=KXJD-T&.VL</2'L&]:@;_#HN%$!#Q`^WCJ*A156`T'/F&<JXS6S'B_)
M53R-C-O&R,JM;Z-*HVN-(UB&9I"13$L&+YW\0:-"]1FGE^J\0#R^HQ0&5-4P
M5GG$7)G%]:S1@J\161<96\L@-?M4.F_;M7IHJ2=Q$BBHSE6D?*,7+.18JI'2
M<()*`)=^GI,419HLNZ(L'X,Y(X1Y*TZ>R#@_(,5D"D5JXVB@S%HC&TJRAD;3
M2UTVUG8-GLPPC4Y%O$N%`(=VV\UF8P&`BINDVS-%#G(W>0[:6++7)TFT<K:.
M\L,(X,TF&]+BKED5A&.DU#I+-G<Y0JU8X(CEN<@@HD#DRA/I+J*A152EXX\O
M^,W+B`>67CCF:EY5CXL4@F6U??JHST"9?<$"V"KRJ$=98(RPE$">K:(]8@/3
MOJ:J5(9^_8Q3%Y)RCUI&QL>U7>R$@_<HLV+%FU2,LY=O';@Z:#9JW1()U%#F
M*0A0$1$`#1%6-<N])VPJ+89&L37+BB/96)5.A(&J<+>KU%(+I&,15$)^EU2>
M@EU4C%$#`FY/TCX#XZBH12VXW<N^-/+ZMS-MXU9CIN7H2MOFD795JL\7,]K4
MF_;'>,HVQP\@V8S$$_=-$Q532=()'.F'4`"7QT!!R11-F^]!VQ*W+2T'.<MJ
M1'2L'+24'*M%J_D$3-)6'>KQTDT,=*GJ)*':O6QTQ,0QB")=P$0V'2HK114+
M.G&CN$\-N8EIM%*XU9UK>5K12X)G9K/$0D9:6*\3!2$@,6SD5U)Z!B6ZB2[\
MOE@"9SG`?:`!XZ5%:*:U7-XBYS<3L\9;NV",3YJK-PRYCOXY\WT9LUGH^7B@
MK,RG7Y\4S3,1',I/X3+K$16](JOT=0&_$'JU-4JI-3\[$U:!F[//O4XV"KD1
M)3LU(K%5.DPB8AFM(23U4B)%5CIM6;<ZA@(4QA`O@`CX:(HT??BXJ?=9^^M]
ML4#]U[X)\Q_:W\.L?P;X-\<^6_6?"_@OS)M\;_B_1Z+S.KQZ>GWM144KP1<+
MSLY.LN*?'JTWUNHBK>9P!IN,(I0Q!._O,XV<DCG9D1W,I'U]!)60=>'3Y+82
MB("<NJ]M[27:OJ+8/W%@ZG>@9#\HT'HJ>"QKYK;V9L;:,VH1'_>DWT4`PJ)'
M`UDIRB;5Y[0UM"7`'3703=F%PYDWKF2DGKAU)2DD\4,J\DY2075>2,@[6,(G
M5<O':QU#F'Q$QM;`0QM@@8UGOC.G->9-S</N9W32$ESG$DG,UX^D\>U>\-A#
MV;`/T;:Y.)ZE\@LAXARW9,!Y6I.9*FF#J2I<F"LI$&`AD+33Y`OHK?4GQ%"F
M25:S\&JJD`&`0(MY:@;&(`A3]5L6ZI8NL6X2.QKRIB".T$`CM"N7:6X[S:NO
M0:U:4+HG8M=BV1CATOC>.+9&%S'5K@:TJ%WOE#BB`Q'E,KZA.4GN#LRPS7+^
M!IH@B+5>C6T0?N*N)S'4Z)*CRK@[%=$QO,21!`3@!C#KJ:+?MO+86LS2V^BJ
MV4?OC<"1V.%'#L.&2K/F!MR+1=7%[I=7[=OXQ<VCL_H),0QQ^?":PR"I(<RI
M/>QC[YR?\,W_`+\NJUX7XKO:K"H[D5D;#N*IS/F5Z7A^O+HL'%L?JJSD^HJ0
MC*ITB&0-)7*VR*QC$(W:0L&BH<HF,4#N#))[@)PU3]2NONRSDN3)U,#?<XN)
MP#1VEQ`'I5R;2V[=;HUR#2+;NE[JOD=[L<;0722N.`#8V!SSB*TIF5W#D?E>
M"S%E9U)45J,5AS&T+'8CP3`%W*C&8SIA18,Y7RQ`/X]<)$JTFN<??-Z@@&$1
M)OKK:/8NL+?PIJ&[?])([F]^)H>3<&CL:/74]^[A@U[6BW3@YFAVD;;>U8?P
M8(1TL)'SI#U2R<Y)'98`8/\`V_H_7U6VD=7>R5CG+!?"\;)/&JC9<#?6D,03
M%$2'3$?$BB9R[&(HF8`$I@V$!#<-/!\5DENX_1.R4LD=$\2MS"VXNV9RA/R1
MXZ1+.S2)7>5<2F:4'(8**`+N3,R:%&LV\Y/`YDK1")E.H?Q`7J+@OY.L"[JT
MAVEZDXM;2VD<2WE7\(>W$=AIP*]'_)'?;-Y;1CM[E]=8L`V*2N;V4^BD[:M'
M2[CUL).#A6&/>\9P\K,=M>"L,6SFZ]9.=]!K-@AY!!-RRE(*Q1+^%EV#E!8I
MDSI.F+XY!W`=A$!#Q`-6P5F0KL?:TNT_QRS#R/[5^49!RK)<>YMYE'B]+RBA
MA6NO%S(4NXE(=HR65,(.G&/9B1]$N0@G%/SQ3#8J`[!G1!R*]/((H#WZNW^;
M8-PX?<E@WV#<`%TZ^GV[:<5*QUFFIMNYWW0K+Q7R#(O)'AKP.IE,O64\:-'[
MAK"9HSY>A4>UF'N)6:S5P^KU2BR'ZFIQ.0%6JX>`.@,5F>Q1FKO8["^'HBGE
MQ[%XIQQ'T,K(T<%+:4BM(546"@;*LSP"<86*4;J_ED,D(''Q'<=2IHJ$;KC"
M#[5/<UX\6?!S5&H<2.X9/R6&,M8;9N3(4JIYH20(YJMTK40JHHUARR*CU(/*
M12`A$O6H%Z4UD"HQD>Q1DLM=I@!XV<F>X=V\9#SF49C+,@\A\(QRJ8D;GP]F
MI-%Z=&,V;()^C@Y06B1@((I$7<'3)^]''09D(.W-3@[HG(Y[Q=X.9UR/7%3?
M:+,UU'%^(F"`CZ^5ROE1XA1J2UC$P$HKOF<E,^M!,#%,<C0P%$#;:')254'F
M7"-TQOC+MI=D7$-JG*/]M56E[MRZOM6<ILK*ZQA54B6+,#5I*-Q;NRKW^XRT
M@BHL<A3KI))$4,=,[@@J84&2@J_["?%GCQQTH<5C;#.'J#1*G$Q[:.*SB*U%
M$>2A&R8I^KL$J=J>2L$DOU&,JX>*K*G,8=S;>&I4JE?NL\;(/A?(4CNH\2("
M)Q3DO"%VJS;/U9IC).NU3,N'K7.QM>GVEG@HDB,4>005>ID6<`V$ZB2XN%!%
M=JB<(.&*BB[)SWL<EW`.5W$GMT4Z[S56P'DG%:W++DY(UA^K&SUPQ0S.V^2,
M;J.$1378LK0].4ZX=1BF]0DJ)3>F$AAQ17%8OXN<<L*U%C1<5X/Q?2*K'LTV
M"47"TR"2]0W2)T%&3>JLUI"8<&+^.L[566/^48=2E`N^4C%F,<9FGCXXQU1<
M?FM4BE+V8:54X&J_,,JBW!JE)S80;!B$I()MB@F"R_6H!`VWVT4JD?L3U"KV
M+C_R@=6.IUV:72YV<BF[9U,0,7(N`;)OH$Q$2.'C19444S*&Z2]6Q>H=@#<=
MX"@45Z4-4*E7%UW5>J]=@7+E(J#EQ#0D9%KN$"'\PB*ZK%L@HJD53W@*81`!
M\=2I6F+3ZM>J+'<M.X/A.&,^RGP*[F.7;%=8R,(*<CD3C1:6T4CENF/1;D\V
M02C&+Q1\B4_45NCZA0NQB@.N/:%Q[5M@77)-/S)PZO&5L?RR$[2<B\=;A<:O
M+-S%,F]A;!CN3D6*A@*8WE+E1<`55,1ZDE2F(;8Q1#7)<EK?=)?^U.Z>DO3]
MBWXNP;?[\M_9[/;J*847'Y585WML,6VPTC$^>(B0DY"JXFE):`N=7()E(V+8
MWA2-08WTK<A=B+Q\C'I,'*IA'H0>%'P*4XZR%L*_AANI+.0`/>.H'GTC$>H'
MJ'K6KOQ.;?OKS1;/7X'.=:6SW1/9C1IEH6R4RQ+?#<<ZE@R)IKTF,#A3K*'0
M4"!X_0/A^T.LNQ1F"*KCU=1J%HZ3PXA>0]@>S]CV:*5\;]RFS:+NE"&.5%,3
M"0@"8Z@^PJ:9"[F.HH([%``$1$=@U#9.EQCR+Q2O)<FLZW`<BK1<E6''_%KC
MIQ9X[YHP=3.2>648VUYFFJGDNP3$2TP!!Y-<IO(>EPJU>3-($<O?+.*S1<W0
M15%90``ITBEQ_9V>HZOJ=U=:?<.@@:X,ZV`'Q.@D%V.%`3T@C,#L6S.IZYH6
MP=I:1MO<FFPZMK)B?=/CG<YOV1MST.9".GO!SFM\1['#NN<3AU44>?O&\>/_
M`*X^.O\`[^R-^XU5?N+6_P"LKG]JWY5:/ZS-D?\`J.E_QLOR+.N!LIXNS,[R
MSQYQGQ[QGQ-RAGS#MGHV.LI8^LL_*/IVPLU6MD-BZ87LY$RQ$1D".BEFAEFJ
MJ:QS_5^)C)AJEWND:M8!FIZC.^YMH)`XM<!4--1X@IF8ZAU#7`$\%<VWMW;;
MW8+O:V@:3::-K.H6<D4,T+W.,DE6/%LXO`Z67(88BX$'J+1D2JT$$%V8KQSV
M/5B)*)<.(>5B%TA0<1,G%KJ,7\<X1,4IDG#)T@=,Y1`!`Q=7["]KH&AF+*8'
MFM<[F&2"X?',")0X@@X$$&A!'`@X$<#@O>([!N`;B'T:Y]/5W<E\$`>CZT=C
M=8;`7;?8=M0X"X:(8S1[#FHRSR5T_9.Q->GV3,L9W0F)*&QHPKZ6,58A-,GP
MV_6TSMM.*.%C*D,`EH300*51+I/YTD9/JZ04*.-?,&_@=%'8D--R'5KR`S/K
MR]1Y"FV?PPZ!JQU2ZW"'21:0R(Q$?@S/>00W',1@=9(%07-%0"X.S%WM@_\`
M,_:\'Z0[B&(MA#Z/%36*R./:MT2<0%W7NZX^MN*!P9W,L,12[W*7">S"ZR1$
M1J9_5Y#XQW%PE%94JKX$=U'2<$U=#(-]P$&Q#.5O`2@(#S4GFL7W7(E1R_WH
M^V5E6@2Z$]2,A<&<^6ZKS+8P&1?0TZD>18J&`!$45P1<`55(VQTE2F(8`,40
M!Q3-<EPC.GBCO)=T3%%L<),K#F:%P[GK'J;CK3&Q5)&*6C)H8Q14A$W8PCN7
M035(F)A*8JO\"ITN*<5?1J5*H1[OBJ61^5O:5X]5ITDXO\ORX:9?=1Z"*CI[
M#T#&S)L]FK$[31'K;1HF*J3K-L!_(4$/!(^T%05RW.Y1+BKW/>`/,],Z<;2<
MTA8N%>;WP@"#,B5KZYS%LQ+N-A*(-+$H<"G-XE(T!,@;JCIQ3BN<Y?J*\K^Z
M5PKX>MB!(XVXQQ4GSHSRT`/.9+S\,LK4L$P,PBHCY)BELKM1[Y0F4(L@L/60
M-DS@S-$S77>6DNQPYWMNWCEBY&58TK+.#<R<>H6;7*FC%M<B/'XR<-&+O5U2
M)$6E1FT$BE_&$ZA`#<3`&G%.*O>U*E4^]]RZQ-7[9F>JVZ51//Y;6HV)J1$B
M;=].6NV7:"],QC$"@*CEXA'L7+GI*`CT(&^G;4')0<E%.G,W?&GO+<4XS)QF
M<&AG#MQU+"-8D79Q(T7R7BQ5JK*55-^8`9GE79V)BI)E.)E#*HE`!,J0!<:)
MQ6Q=J5*K]X_\S++F7FWS3XI2>/X>OP'%IEB!W7[JSGGC^5N@Y*@Y"5?EE89:
M/;M(<L2LR`B0I+K"J4PB;I$-1Q4*D;M:\$*ARPQAR/O4[R"Y=XC>1',K/=5"
MOX"SY/8MJ;M&-EX]TG*OH&*8N$',XY^("19P8>HZ:9"^PH:9J*`J_KB9PVK7
M$1O?VU<S7R6S&3(+VO/GA^1>8YC+BM<4KK63:I(TY27:-1K[:4)*"9Z1/J!R
M=%$P[>6&@%%(%%6CV982(LI^Z=6Y^/:R\#/\\LP0LU$OD@78R45*P$<QDH]V
M@;W56KUHN=-0H^!BF$-`@R6.N'\W8.(RG/GM1Y%D':T/B_%N5\X<-IF86$5[
M3QOOD#87+JJ1ZZANA\XQQ8G)TE")[G**KD-@30`"AA@G8HM=!O\`M4NC;WOL
M8VV_5^W/;;;;\.E>ZE/[ZVL;O3:[D2GV>AVZ.1EZQ<(*4KD]&N"E,D\BY=FJ
MR>)>\!NA3R5A$AP]XAP`P;"`#K[V\\EM.VXA-)&.!']W(Y'L70U;3+/6M,GT
MG4&]=G<1.C>.QPI4<B,P>!`/!:/>=L72W&K,N0,%W!^F9_1I@4H:4=G(V/8Z
M9(E%[4K(F"A@`_Q&'4("W3N!'*:I/:76PNAZC;ZEI[;D/`:&@])./:/2#@O+
MC>FU+_:NY+K1+ACG20REH<&FCFYL>.Q[2'#E4C,$#%GQZ%+X?%&'A_*D/W>J
MG4/[PR*M?[/.,"QWL*FAP;QW2;MD:SYWR<NW4P)Q-@TLK9`4$4EVM@MC0RKC
M'M'3*8%&[UY)S#0'(MC;^?Y*:(A]>7>VMRZC/#;LTRSPN[IQ8#\T4[SOR1CV
M8+*OE9MVRN-2N-S;A9_V]H\/VB8&H\1U:00C`U,LH`H<"`X<5'3).2+1FG)=
MZS%=MU+3D6PN[`]0\TZR,.P.)6\'769E#&$K&O0J*#1(/8()=7M$=5?3K:*V
ML8K:&K(HVAHYD4S/,G,]I5@[DUN\W#K=UK%^[JNKF9TCN0+C7I;R:T48T<&M
M`J<UU#J-_:E_J_9U4*-YN5!HA7<I%N8Z:@)%>(L4#)Q\[7I1J<4W<7-Q#M*0
MBW[<Y!`Q%&CQN0X;#X[;>S7S?"R9_P!-W@YI;C[M"*$'TC`KLVEU-9SLN+=Q
M9+&X.:X&A#@:@@BA!!`((Q!%0I<\K6<5D./QYS.J#%O&UWD"5:`R_!M"@FWH
MO)6J-2-KHQ.F'@V87IHV++LQ,/UHF4..PJ``VWI5Q]W7$FBW3^[`1X;OG1.)
MZ#Z6XL/:!S64/,&RBURTM/,#3&`0:D"+EK<HKZ,#QVTX-F!%Q&,J/<``&T$/
M?6MND#`NEXCL'UA/;OX_E:N9CXW/Z6'J-."Q26/`Q!"Y:M5ZPY!MU6Q[16Q9
MBZ7B=C:K5XU,X&!Q+RZP(I+*](CY3)@D)G#A0=BI-TCG,(`41UUI[F*PL)IY
M3T.-37D!F2JCI.E7NLZG!IMC&Z6YFD:QK1FYSC0#VY\ABMV[CC@^N<<L*8^P
MW6.E9E38)!H_DQ3*FO/6!T8SZQV!WL`&,YF9IRNN/5N)"G`F^Q0UKSJ=])J5
M])>25[QP')HP`]0_9J5ZE;-VS:[0VW:Z!:@4AC'6X"G7([&1Y]+B:5Q#:#@H
M1=R[B3F;E-.<'W^(4Z@HVP+R]Q]F7(PVN><0BB=$KH*#*JP!$(N2"5F2^`)M
MC"B!]_QP\=J>:\%="LTL$##VJ!FJQ8HYK+U^QQ,C!3D2^2*LRDXB79K,)*/=
MHF]U5L\9N#IG*/@8IA#4HM>OAYVP^57&SG!A2Q3,CCRR<3^,4;R6IN$[(-RE
M'&36V+\RJ*3]2ILO5UX%)F12K6!\X3,H1X8G0<YBB)>@@0N-#7L4[NX#V_9[
MDY8,6\AN/643<?\`F3@$[K[+LJE9*/H.P5YZH=>1QSD1@W`SB0J;]594Q!`B
MX("X7*9%9-<Y-"%*P:US'WVV$6%-><->&T]:D>F,+F9'D%*1E`<G+]6%E<8Z
M,U^<A;&#WSMTUD5!-OTIE#8@,4Q66>%/;_R)C/,ETYF<RLKQG(#F5D"#3JC2
M:@(M>)QEA*@[BLI0,1P[XI7;=LY5.8';\Z:"JY-R@F3S7!W`5XYIVK*W<YXE
M6#FCP_R!ARC.(AAE%M*52_XFE9UZYC8R-R%1IYI,1*CF3:(.G,:1\R(Z9^H(
MDH*'J?,`H].I*DK'?;PXMY\Q?=N4?)3EN6C#R,Y+7:GD>-*#./[-7JOC'&E-
MC:W3:Y&S$DPC'`)J/COG*B((_5]28"HITATPH`6=>=?"7''.["3C%%XD92I6
M"$F6=SQ;DVN`4MIQED.'(K\%L\.?S$#KH$,H*;MKYJ0.D#"`'34*FJG*E0,J
MUN[Z>"H9OC>:P/Q8YE)P3%.,@,XM,T.\.S\ZT:!Z5E(7^L6./4!Y/JH$(HZ,
MQ(D50_4(JG.83C&*C%<EBO@3RHY&\B<=<K^YK?\`'$NXPF_^.X"XGX33EG6&
M\?VE4I5"WBXS5B`'MSN,>L1,R/N*HD613,"YDDRI"IQ2G-3&Y\\$,?<[\5Q%
M2L$],8[R7CV>3NV%,R543$M6,+PV!$49-@*:[15W%OA;)%>-BK(F4\I-1-1-
M9%)0HBJ%09K5E[]F#V2%"EL0<1.8["(3*QB<O%R?(X?M$RR;'%!J\M\+)-VK
M)265:$*986K3Q4$1,JJ81-IBF*RKV^.+O+2A<F>7G+/E=#X;IEEY01F)F[+'
MN);78;>C6%L>,IN,<%E)29AHYLH*[-VW$HMUG`'4ZQ]P-@U.*#M42N*G'SN^
M\(Z_ES'V'\,\+KW5,@9]RAF-K.7[,>0HZ;*6\RJ2C=HJS@JLFT(5-@Q1-L(]
M1#G,41'8!U`!"C%60\9+EW0)S*9F'+;"_$FBX=^5)AP6PX8R;D"U7CYR2>1)
M8*.&&LD,SBQ@G3%1Z9RMY@*IJ)I`4!`QMF/%3BNC]M'B5F7BQ*\V'>725`B&
M=N6]YS%CP:I/.9LZE&G6,<WC59TKB+C/A<P=5N?K;%%8"``>^.^@0+X>Y3PN
MRGGY_@[/?&0]/8<F,"3EBB(\ETE7=?KM_P`-Y-@7]6R9CJPS,?'23HK1TS>E
M<MBF3%,I@7`!(=4#@[4/8L`?T>G(+^A/^X5Z/'WVZ?*/P;X=\UO/D3S/M=^<
M_0?-/P3U/E?+ON>9Z/;SO=]GO:<$X*]34J5C.XX6P_D.41F[]BW'MUF6[(D<
MA+6JG5^?DD8])95PFQ3>RD>Z<D:)KKG.5,#=`&.80#<1UW[75=2LH_"M)Y8X
MR:T:X@5]`5IZWL39FY+L7^OZ797EZ&!H?+$Q[ND8@=1%:"IIR74ONL\9_P#E
M]PO_`,,J;_X/KNC<VX0*"]N:?PCOE5&_5'Y8?U#I?\WC^10Q[B7$=K;>'=XJ
MO'^LP]%=U2?BLN/Z+08*)K<9DI.H)G5E(.690[)J$D_^%E%RQ`VXJ/63=,?`
M0Z:OM[<$YUELNJO=.^1GA-=(XN+*N!%"3@"<#Z59/FIY:V0\O9[#9=O%8Q6\
MWVI\$#&QLGZ6%KNH-`ZG-;WV8YL`QP6JFP<HNVR#EJJ)T'")%2>`AN0X`8-P
M'82B'X/:`ZS9UAT;7T%*4]:\]GM+'EKLP5]FN-0B]9CE3ZUC#[A`'J$?87;?
M??QUSE8Z6W%NW"0NK7L7$>_7@MA+M+\4HZS<<LAW+-]9C;ECO.]RAK'3L972
M)CYRJA%T=%S%Q^0@A91JX32F[$^44*BN'2)F+-N<-P,`ZQ%O;52S48[:S<67
M$+"'N:<>\0>FH_Q03VGL-=W_`(?=BQW&T;F]W'`R?2KR=CH896!S#X(<TS]+
M@14E[F,(X-<:GJ'39;]Q?AH(;?==P5MOOM]FE5VW_#^;=6FS7];C/4R[N`>Q
M[OE6<SY<;!.>C:;_`#>+\U=JI'$[C)C6T1]VQ_@/$E-M\2F[2B[-7*)78F;C
MB/VYV;T&,DS8).FOJFBADCB0Q1,F82CX"(:^-QJ^J73#'<W$TD;LPY[B#C7&
MIYKNZ=LO:.DW3;W2],L;>\97I?'#&US:@@T(:"*@D>@J06J<KG31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:<O<6XXI<4>2<VW8
MD0C<4Y>5D[]C1<W0W8Q;ER[!6Y4E,QA!,AJ]+NO/;)@/@P=H@'XAMLZ[.UJ/
M4=-\.X-9V8$'B[G^4,?34<%YO>=.P9-F[LD%FP_=%T3+"0,`UQ[T?IC<2T?B
M=!XJ#7Q^#_UW&_YVW_QFKHJ/FCVK#WA2_-/L6;>-F%GG*O.E$P96WY?26)VI
M+7>8CU".#5W'L&*;JT2BATC&*@X=-S%9-!.(%,]=I!X^S5+UK56Z9I\FHAP+
MVBG3VG!H]9IZJE7GL#9]YO'<]KH<#7!LDE7N^9&W&1YK\UH-.;BT<5N[UJN0
ME/KL%4ZU'-XBO5J(CH&#BVA.AM'Q,2T28Q[-`OB()MVJ!2AON([>/CK7J::2
MXE=/*:RO<23S)-2O4/3["UTNQATVQ8([."-L;&C@UH``]@SS.9Q7-Z^:[B:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(H3\T
MOS%0/YEGY]EOYYOYD_-B?Z`_[<_RO^3=.JQI'OO_`$OA]1GQ][_!ZU8&_/JK
M;^@\Y/Z1RR;]3_I/R%`3_P##C5Q?\Z6-/_A%+SAK^GEP_P#CN_1)I_,Z_3K\
M[D_2[_TI_!_ROIU1-6^H'Z=]9^[>[D?\KEV=2OG8W])2_P#CGZ/_`,/^M]]O
MO?O?/\;H5B^J`LHIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
(:(FB)HB__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g628690tx_pg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g628690tx_pg04.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*0"``P$1``(1`0,1`?_$`+4```$%`0$!````````
M``````@`!08'"0H#!`$``@$$`P$```````````````@'`04&"0,$"@(0```&
M`0,"`P,)!`L!``````$"`P0%!@<`$0@2$R$4"4$B<C&R(Q5UM3:V.($R%QA1
M85)3M-46EE=X&3D1``$#!`(`!`$&!P\%``````(!`P0`$04&$@<A,1,(06%Q
M(A1T%U&!0M.T%36AL6)R@K(C,[.$E%46-SB1,B0E&/_:``P#`0`"$0,1`#\`
MZ+N</._/F+L^6+%^,)B'J4!3F,"1=P>OQ,Y)3<A,PK&<7=.5IIL]2:MVQ)`J
M*22)""/0)C"81`"ZQ?<U[I.U=([5F:1I,B/`Q6.:80B5AIYQYQYD'B(E>$T$
M11Q`$01/)5)5NEMC'MV]MW6>X]:1=QW!A^=DY[CRH*/N,ML@TZ;2"*-$"D1*
M"D1$J^:(B)9;T7BKU2N057M35WD]>)R53ESI(RL2E!PU;FF;?N`*KZ"D(=JR
M0.^3((_0NB*(J@'3NF(]81?HGOB[9P>="1NQ1\UKQJB.M(RS'>`;^)L.-"`J
M:)^0ZA`7E<%^DDC[I[-NL,SAC8T\7\1GA15;=5YU]HRMX`\#I&J`J_E-J)#Y
MV)/HJ87)K/G(9OCV+Y,\6\OHV?!<P1,ECA%Z947\UCF1ZTVRH/1=0IY(L<D\
M."+I)R)UV2YBB)SH*%.5A.ZNUNW&M18[IZ.V`9O5\A$20R4.*;V/<N@KSY,J
MYZ:&J"X+BJ;)JBJ1-&)#!/4/6G5KNT/=1=R8(H?8["JK#PRI(-3@LI)PXN^G
MS444FR;1`=!%1!%P2%<\O_2/F'_R;&_[$I7^2:4?_P"R/<-_G3/^!A_F::3_
M`.3NB/\`)W?\9+_.T\5_U,^6<5-Q<A+7&!LL6U>MU9"!?TVMLFLHS*J3S+,[
MR)CV,BT,LEN!5$E2F(80'8=MAN.)]Z??<'),2Y^1BS80.BKC!Q(X"Z%TY`IM
M-@X%TNB$)(J+X^/E70RGM$Z1FX]Z+"@28DPVR0'@E/F3967B2`X9@5ELJB0J
MBIX>'G73'&/2R<;'R1$S)$D&+1Z5(P@8R97:":Y4S&#8!,0%-A'6Z.%)2;#9
MF"BB+K0FB?@Y"A6_%>M14R.L.6[$)>1-.$%_P\24;_CM68?(?./(S(O*IGP[
MXV66`QBYB:.A>,B9-F(A&=D6+)VFBY3:1#)TFX02(DW>LR`)4P65<.MNXDFF
M83=FN!/*ZU]R'%OGS!KMWT-SW4F'!%D5%V5JQ;".(U5,%"BNB!2J/1*!T]P`
M>@=A'Y-5JETK3!9RWC6)G4F^;MV[-N"CR0>*HM&Q"ID#NN5U5#)H-TQ$-Q$1
M`I=%4J.U^_T2VN%VE5NU1LSIJ43.6U?LD-,N&Y2CTB9=&->N5$2@;P$3`'CH
MHJ0&DXTL@G$FD&)955N9XE&&=H!(*-"&Z#NDV0J>9.W*?P$X%Z0'PWT44P-[
M]17<X%8:76I.;*/7M7F]CAUIP>T43J[1*;PS_P"C*`B;Z/P`/'11:GR5F(F"
M8K2<Y*1T-&MP`7$A*O6T<Q0`1V`5G;Q5%ND`C_:,&BBFNNW.GW!)9:I6NM6A
M%L8"N%:[.Q<VDW,;?I*LI&.G)4C&V\`,(;Z**\+!?:+4S@G:;I4ZTH8`$J=@
ML</#',`@`@(%D7C8P@(#X:**=82P0%E9%DZY.1%@CCF$A)"$DF4JR,<NPF(5
MTP670,8`'Q`#;Z**Y?O45_6)EOX:5^1:YK1O[OO^0^?_`+G^A1ZW*^U;_8?!
M_/+_`$Q^@FTM5,)6A'IX9F3J.55L*6_HE,5YZ0<4Z<@GP]R/2LDBR591#\J1
MC`5,9=(1C7&PAW"K)".XI%V;7VB]C!K^]%UML%G]%VH2B/L'XMI(<!0:.R^"
M>JEX[EO^Y#!5\0&RO>Z702SFECV#@KL[GK1#*9>#P-6`-#="Z>*^DO\`3A?R
M431/`UH5L^XL<84S)D+&"QE54*K87+>(<K!LH\K[TB<E7W9_Z5%8AXCUC_>`
M;4%]JZ,[UKV+E])<4B:@RR%HE\S8-$<8)?E5HPO_``KU-'6>YM=@Z%B]P;1$
M<FQ1)T4\A?"[;XI\B.B5ODM50>T/B+\X-1^GFGSI^_6<_#\5=J54_"];^P(?
M[N;Z](^"_8</[(S_`&8UY^<U^V9?VIW^>59:T/\`^P6;?^N]>_P6.=73XU;O
MR:T3S7F6E8!QQ/94R$K)H5.N'C"22L/&JRT@4TM)M(AGV&")BJ+`+QZF!MA]
MTNX^S5:^:RG]1#*5.NN0.'5%OUQD:GQIR2@YR9DA8'$A$A+P!48IS!-ITL>"
MKTC<J3D4Q3`IQ25<]8!UD*8M*^D3_K0R<FK/P(QS!T#)O"&X5FJYNI&1:PY;
MMZ*_M[<TU6%E5DIMM,H3A1:/6I`*D"FYP,JD<Z9P.4_@4)>_CY427*S&S/.O
MJ*\?\?2=GMM,B+G@"5/-R='EC0U@7B6JUOFW4&E)%*?M,98S0J*^Y3@*8C[H
MCMHH\DJ!<W^(^#^*E;X_9!PC7Y:JWIOGNE12UK/9IR3EY!NJ#N0.H]4?O5D?
M,^;CR&`Z)$?`3E$!*80T4(JU*^9]SQ1:^>-$QCRCN'U'QQH6+R6U:O/7\PSK
ML_=Y=5\+()E.$*=ZNHX3*F0!#I$$FQB`8H*GZBA/+P\ZJFS7+A]C7DSQ1MO!
MFW0D9)6#)K"@Y6JU,?65*#F:A9'\5&H'E(Z=(5`ZASO%BAVQ$!.5,_24Z8'$
MH\;>-:/<AL.>GLKD-_>N2B&*T;_:&<85<][O#J,>NF44S3C6"S:!"P,R)($;
M-BD[I6X%.8OB83;ZK5$5?A0:\87&'\>^HW(T7BS9XQY@V^X8=S,S!5BQKV"I
MMK9%*&7$C(ZSIYVG;`&I#``G,=(CQ0@"!#`4*55?+Q\Z#+U%?UB9;^&E?D6N
M:T<>[[_D/G_[G^A1ZW)^U;_8?!_/+_3'Z";2U4PE3K%JSQME#&CB.ZP?HY$H
MZC+M[]8NBVB*%$"[>.YE-@_;K*='<D,[OA78E_K0Y>&H6\^226N/[M8YN+;#
MNGY=J5;ZL6*EH=_+BL=R_P"Y1L>J,BS3Y8RRC;I[[BA4E60Z1#J\T5N_02ZP
M]AO)))?LVTR?O@;CAWU()FWJGBH:N?QN)BE_EX(/XK4O?LX<?/I-@7;^F.3E
MH'\7D"K;^6I5G;[0^(OS@THB>:?.G[]-/\/Q5VI53\+UO[`A_NYOKTCX+]AP
M_LC/]F->?G-?MF7]J=_GE62^?BY&XM\ZEN6Z6+KAD[#]_P`9,:+;5Z%'GF9N
MJ/6",:U,JXCDO?3+U0+19,ZO;;K)JJD!4JA0`;I5N2RI:JNYA<UJKREX_P!R
MPIB+#/(F6M]L7K8LA>8M?(,6XP]DBIIP5<S%Y)NCF418&3(!$A]\P"(@&XZ*
M$2RU.>4N,+W5@X*\@OX53>3*S@VG0E>R[CV/A"3-@8QCVMP*2[A6MN$UC//(
M+).2*E,F8B#A-/N"0HB<I1\E6#$<S.)UIDXF$I/$[)]IFY.2CF/DFG&R*:EC
M0=O$6RSR2=+)"FW;QI5!55,7KV(01`=5JEJ><F5N?6]4[CI86M?FE:U'8/MS
M%Y/-XA^I`L')VMZ*BS=2R3<8YHX/W2`1,ZA3#U%V#Q#11\*7JHUVPV3&6$&]
M=@)NP.&?(.E/G:$'$R$NLU8HLY8JKURE'MW"C=HD)P`RAP`A=PW'10E5]RNK
MLEA?FK2^4UJQ%.Y?P?-8Q4Q_<T:Y5FUU>U.8;K.A:R3FO."*E%+MB@=)8X)D
M,`K$!0#@4IRCS2U6GC+E=QER3D.F5/&?%_(CF3EYYBV-;5>/L97H&FFW,LE/
M2\XJD"T<W8K)%W5(7=,P@(#HHM0?W+^'^%>=/(RY<M<'V[*-6R*VA'6'YYOC
ME;)<*G'HMF:1V#)JL51BBY1;HE:^&ZK<Z`E$I"J=1J57X>%27CLP+8?42JF1
MJ5QMN.`<526%;,S@64U1$Z>UEC-Q<)&L;MA%M2QL.ZF3J`FFBLIYA0B!3^("
M&Q0OE;XT&OJ*_K$RW\-*_(M<UHX]WW_(?/\`]S_0H];D_:M_L/@_GE_IC]!-
MI:J82C?X`89=94Y`UV??I`C1L2+(9#N$LZ`"1S<\,<SFO1J[A02(%5>RR!53
M%$W@V;*G'P+IF?:AUR_O7;,/+2AXZQ@"&?+=+P;%654F&R);(BFZ*&J*O]6V
MX7DE+Q[F]^9TOK"5C(Q<MBS@K!BMCXF2.IQ?<04NM@;51143^L<`?-:J'E-E
MA'-N?LE9%9*&5AI2<^K:V<P"`GK5?;I0L*MTC^Z#UJR\QM[!6'4?=Y;XWV7V
MOFMOC*I8U^5Z<=5^,=@499+Y.8AZEOX=9STUI)]>=98C59"6GLQ_4?3\$A\E
M==3^01\/Y-#][0^(OS@U%">:?.G[]2=\/Q5VI53\+UO[`A_NYOKTCX+]AP_L
MC/\`9C7GYS7[9E_:G?YY4+LQDG/-FSWDK$^,G&*(6'QW4\?6!60O$!;)F1DE
M[LG.&.BF:"LD0V029GA1VW((B!P^78=0AD=R[3S?:F9T/2CP,;'XB!`?5R:Q
M*><<*8CW@GH2&A1`5E?,;^*>?C4Q0-2ZUQ'6F(W;;PS<B=E9LUA`B/1F@;2(
MK-E7UF'2521U/);):H>3E->@P>:^.Z]4D[E"<AHW!5A28+2CVIR'1DJ.I,M8
M*^*CAO(I).&+T56Y%E%.TL40.)P#;6/!WEL_W9KM+\2`FQ1MN;PDA`5TXKEL
M@W#=?8N0N(A`?)M#(N)I8N2):K\?36M_>*FM,RIRX"1JSF884T;"2%X!RVF7
MK(0*HF'$U$1Y"MQXJM3^S91S!;\T7+#>&D<?U\F-:Y5)RYW/(;&=L`.']S2>
M.X6$KU<@96!,8J3!D91RZ7=@4IC`0J8B&XY5F]X[#V'L?(]=]<CB8@X:'%>F
M2YX/O\G)B&;+,>.PZQ=$;!2<=-VR*J"@?%<9Q&FZ)@M`@;[OQ92466ER68L6
M";+/$(JB+KS[[S;WBIF@MM@U=412(D\JB`\I;;2:+R37R;58![D#C:G"GD4Z
M8]?MZM=F]NAVTI47T>67!W)0(N3.BI/4%3N1;B41(<X"`!8/OQS^M:QN3FZP
M8CFV::C*N)$-P8LP9;0N13;]7DXQRY(+P$KG!451(O!*OJ=-838=CU)O4)LE
MO6-L5U`64`%(B%&=)N2!^EQ;>X\5)HQ1OFBHA"*W6K7QVGR@=R<!,Y"GL(C5
MI%J5[,URJU:ZH3T:5TP.LV:1MCD[6Z8/E&KPZ955%6*95"`82E*(AK.]1#N]
M^;$R.VRM9_4;P<WH\6-,%]OD"J(-R')1`:B:BA$3`H2(MD%52L)VD^G6(<J!
MJ\;8OURT?!I^3(B*RYQ.Q$XPW&$P0A15$1>)154NJI>JDQMD3E7F"+L]GJ<A
M@2!@HS(F0Z5&L+!6+^_E1;TJURE<1=O7,=:VK115V1@"ANA,H`(_('R!@.G;
M=WMV#"FYK`/:K%Q;&7GPVPD1IQN\8<ER.A&3<H1520$5>*(GR)Y)G&VZKTMH
MDR'A\VULTG(O8J#+<-B1"!OE+C-OJ("<8B1!4[)=56KC8Y2M'\Q[;"D@S@SQ
M1<$)9+>RK-)\F^/92W-M67#1MWG:B!(4R"AE"$,0RX&VW.(;AJ0XV\9S[X@Z
MVEMQ5@)JR9$W00T-9/UP8Q"-R449XJI(BBIWM<K5@<C3</\`=.?845R2DU=E
M6`#9*"@D?ZJ4@2*PHJNW1!545`M>PU[YGRI.XYL^"(6'8Q;QME'+;*@SBDB1
MT99C%.:[/RYW48+=P@0C\KB*3*`J@HGT&-[N^PAS=C;UE-/S6K8W'M,.,YS/
MA!>5Q"50:*.^ZI-\2%$/DT*(I(0V5?"]E3BT#3,;M>'V3(3W'FWL-@SFLH"C
M8W!?9:07.0JJAQ<5?HJ*W1/&UZ=^0>4W&%,-7W*#2(2G7E2B$W;**<N3LVCI
MZ]D&<4S\\Z3(HH@P0<ORJ+F*'5VB&VV'8==_MG>7.M>NLKN[$<94B!'0@:(E
M$2,W`:#F2(JH`D:$:IX\46UE\:Z/5^F-=A;]C-.??*,Q.?43<$4(A``-PN`J
MJ(IJ(*((OAR5+W3PIDQZWY)'EXB2OULPE-5!\S.Y?LJ75+A&2Z!W#,RK'ZGF
MI&W3$=(-2N3$`QU&R?<2W,7I$0#5LU)KN4LA'F;5/UF3KSK:DX$.++;='D%P
M]%YR6\VX*$J74FQY!=4LJHE7':'>IA@OQ-9A;#'SK;B"!RI,5QI>)V/U6@C-
M&!*-[(+A<2LBW2ZUA[ZBF#<N+\GKC<XO'MMGZO<F-9>0<U7(&3G62HQE:BH:
M09N5(MLZ%D^:O&!A%)4"F%,Q#EW`V^M9?N^ZQWYSNS(['"Q,^7@\BU&-EZ.P
MX^"^G':9<`E;$N!B8+]$K*HJ))=%K8G[5^Q=';Z?@8"9E(,7,P')`O-/O-LF
MGJ/N.@0HX0\P(33Z0W1"116RI0]86X8Y^S79DH.-HTY4(A!9`)VW7:'D8"&A
MFJI@ZU$TY!!L\F7P)[BFV:E.<P_O"F7<X1%UO[<^UNRLT.,@XR3C\>)#Z\J8
MTXPRR*KXJB.")O';Q%MI%5?RE$?I)*/8'?O677N(7(S,C&G3B%?1C1'0>==)
M/)%4%(6@OX*XXJ(GP0E^BIQ\@GKSC]B5YQ(XMX^R/.!+=TN:,N-J58UG%C>N
M$B(2<1&R32+\NZ5?(I@@N=N8S5FR#RR1CG,J<K.=LRI'4VA.=`]'XG,24D7_
M`%QE1AR%*09(@N--N"WQ)31.!JVJMM,_T(*1$9(NO6$=CL_=V^[^Y,IB8RL6
M_56,*6P@L`*J3;KC9.<A0%7F"&B..N_TQH(B`KEN&',O```&*,E``>``%$M`
M``!\@`'U7I'ON\W]/!,%F;?8I/YNG'_UYHR^*YO$7^V1_P`Y3U7>/N<;3.1=
M>A\29$4D99ZW9MO-U"=CF:9EE2D%=[(/V+=DQ9H%'K555.4B9`$1'8-7/#]3
M]FYW*,8G'8#+E,?=$!Y17VP155/I&X8"``/F1$2"*(JJM6_*]G]=87'/92?G
M,4D1ALB+C)9,ELGD``9&9+Y"(HJDJHB)77]",U8Z&B(]<2&681C!FL9,1$AE
M6K5)!02"(`(D$Y!V_JUZ#L;&.'CH\1RRN-,`"V\KB*"MODNE:+,C("7D'Y3=
MT;=>,TOYV(E5+_+9:S&R?7L3?S:YAF<Y43(<[7Y''^)FM,DZO6,JR<>J]9(V
M/_4*!GN.4@3.J@59J!BN#&Z=QZ=AZMTHW?$Z"G?FPY'L[%Y>5B7L3BQB.1HV
M4<;4P&1]83GCTLJC=NZ.*MOA9;TW^G93=_N1P4#KK)8J-E&LGDBE-R)&.;-`
M-6/07C.6Z(JHY901+_&Z6J,-:;:DN-$G!P%-NL?0T.7U"EL/5J;@99&T1^*4
M\CT^2\Z]BWB!K`VBTY+ZP<$4?E\P5L/6J;IV'5ECZYG0Z9>Q>*QV2:U8>P8+
MN)CO,.I);Q:9"(YS-HQ]<6T<]=Q"?3U$;^D:\;+5W?S^%/MQG(Y.?CW=E+19
MC64?9>;6.>16#*;X`X*^@3BM^B"BRO!7/H@E[I1!O[03`O*+,UZR!7KF%#RW
M4<7A5[A5Z?8KI$H2M*CI:(F8*<1JD=+R41(G,Y36;BJ@"2R0CL?<!#4L2\V/
M5?=^Q[1MD3(_Z6S^/QOU:7&B2)C0NPVW6G6'DBMNN-.+R$V^0()BO@5TM481
ML.7973F`US6)4#_4N$G9#ZQ%D2F(CBMRW&G6GF5DN--N@G$A/B?(23Q&RWJG
MK)1+WFB@\[KO4:59FK',[/'[7%\39HIQ6K);$<<UN/;R;YO!2Y6TBP;2SQN=
M-@#I-%1P(`/2`"&H]S&K;1V1JG:6S:_C9K<78VX`8UJ2T4>1*3'QP%TQ8=XN
M`+IB0L(X(DY:]DO6=XG9-;T#9>M]=SF0AG(P#DTL@['<&0Q&6<^9-@3S7)LR
M;$D)[TR(0O:ZVHO,9<E<=W9]6*3'1N2(VU.V"39U%6'%>08!&&>,(T5WC68F
MI.NMX!F='RQR`;S1B**;%(8PF#=@=*[GU#994+6H;.99SKC2"34C&3V$9,&^
M1BZ\Y'%@%3BJ7]51(K(*JJI4&;?U)M6O1YFPRGL2[A6W5(7&,C">5T3<L!--
M-OD\2+R1;>FBBEU)$LM9_8RK?&R(;WTN;\4Y8=WU3,>7))5W'4;.SEFYAW=^
MFW<"Y:JU!$D&X17C3IG(9(!$X#N;??<50TO#],P&LJ/9>"SSFTKL.4<4VX6;
M(":*<\3!"L1$9)%;5%113Q3SO3.[?ENVISN,7KO-81O6DP.,;07)F'$Q=&$T
M+PDDI5>%4<145"\OA:B7NE[C,=\OXC(\[`7U:FS/&%O7F$I7L?W&T`28=Y$2
MFT(U\W@H>0<Q[LL8W,H<BY2&)X`8`$0U,^R;3"U#W!Q]QRD3*EKDG218!V/`
MER;/%/1X6S%AIPFS],5)4-$5/!%LJU$>OZW+VKHI_4\;)Q@Y^/N!/FV_-BQ[
MM#!5I7`)YT!,?4)$10547Q5+HE?-R`R/$W!OQBRG7Z_D)]5*AR&0DK$4,<75
M*P1L='5&T,W,@M5E80EA%B#EXF0BH-Q(H)O=$=<';&XP-A:TG><3$R[N"Q^W
M"Y(_]?,1]MMN+)`G%C*RC_#D8HA(W8K^"K7+UCJDW!.[AIF3E8MO-3M65MC_
M`,Z(K#AN28YB"2$>5CGQ$E4>=TMXHE7L;.V*,A4N]F>5+(-@K$-$MB6JOS6&
M[Z"LO%33D8X[=E7YBMHN+(F0!,=RDV36,BB45#@!0WU*)=I:'MVMY19,#+R\
M)&8%)3#V(G7=:>+TU$&'8Z%(1/%7!;$U`$4B1$\:C@>M]UU;8,:D>=BXN8D/
MDL9YK*0[-.-#S0C?:?46%7P1LG"!#)>(JJT*6,V]&:Y^Q,EQ2B\M0%',K;S9
MK@Y6&RC`XN95TM:=A7@2BLBM&L6QL`VDR`-RQA2GZ.L#!T!J"=*:U9CM;`M]
M$L9^)K*E+7,,.LY)C&!'^KEZ%FL@`M@_]9X>FD=$6W*Z<:FG;W-C>ZRS9]U/
M8.5L2#%_5+S;N/>R!O\`U@?7NY!(G#9^K\^:OJJ7XV7E6G^G;I/*6BBEHHI:
B**6BBEHHI:**6BBEHHI:**6BBEHHI:**6BBEHHI:**__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g628690tx_pg05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g628690tx_pg05.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+`!^`P$1``(1`0,1`?_$`)T``0`"`04!`0``````
M```````("0<#!`4&"@$+`0$``@(#`0$`````````````!P@!!@($!0D*$```
M!P`!`@4$`@$%`0`````!`@,$!08'"``1(1(3%`DB%187,2-!,D(S)!@*$0`!
M`P,"!`,%!0<%```````!``(#$00%(1(Q01,&46$'(D(C%`AQ@3(5%O"AL5)B
M,T.1P?&"%__:``P#`0`"$0,1`#\`MH^?;Y(M"R2SY]Q/XW:?:\XO;%-IINT7
M7/;`[KUEA(QVW70HF?IS$<=)ZR-.E45EY%,ARF%HDR*/=-P8HP-ZQ=^WF$=#
M@<'.Z'(N^)*]AHYC/<:#R+M7'G0#D5>_Z1/0S#=W6UYWUWQ8Q7F"UM[6&9NZ
M-[P09IBT\0R@C8?YC)S:%0-DGRE<[<JT^@:1)\GMYTZ(I=KAYZ=SF\:?9I^J
M7J`:N/)/568BI)ZLS63F8=9=%%02^9LY%)<@@=,H]0UAO4SN['Y*"]O+VXN+
M1D@+XWO):]M?:%/&E:'D=5;SNCZ</27.=NWF)QN$QUCD9[=S8KB*(-DBDI[#
MVD>#J$CWA4'0K]$+(-6I.YY=0=ASF62FZ/I%5A[=6I%,R8F5C9AHFZ30=$34
M5*VD6*AS(.D1,)D'*1TS?440ZNG8WMMDK.*_LW!]K-&U[2.;7"H^_P`1R.B^
M-G<.!R7:^<N^WLQ&8LG9SOBD:>3F&E16E6N_$T\VD$:%9'Z[:\=.B)T1.B)T
M1.B)T1.B)T1.B)T1.B)T1>(C_P"ACAJYQ?D7'<M:TV<?K?DBLUC;HY5556:U
MO:ZY"(,BI+K+JJ"V87JFPZ;AJGW`A7<:[*4``Y"]58]<.U9+/)L[IM@3:W-&
M2_TR-;1I^QS1]Q:?%?4CZ+O5"'.=IR^G%^YK<MBJR6_`=2VD>2>`%3%(XAW/
M:]AUH2J"*16)_3+I4,WSYB%EO5_LT-3J;`,E$U7,Q8[#((Q<4T*4AC"1(73@
M#+'[>5%$IU#=BE$0A+&V%SEKV'&V#2^ZFD:QH'BXTJ?`:ZGP5R<YF<=VYA[G
M/9:1L6,LX'RR/)``:QI<>//2@',Z+UT/>5UR^-ZLYSP>XR.*'983C]2V\'JE
MTN$),6)2T;98W[JWZ&>"!G8X%.-A8Z:FE2^B)#BDLL9O]/MQ\WU#]._3&PQW
M:=K9W+I=L<8#:.`J-27&H/XW%S@-*-(7Y=?J:^K//YGUBRU_@(+-S'S?$ZC7
M.VN`#61-V/8/A1!C'N-2Z0/Y!2CX0?*5IVM[S"Y1O[?/V$-H#1:'H\W4X&5@
M%&E]0$SR/B)89"Q3J3AG96*:K=N)02,1\1)/N;U@\OL]Q=E6V/Q[KW&NE<Z/
M5X<00&\#0@#4<?LJM(]+/J`RW=/=47;W=,5I%%=-+87Q->WXW%K7;GO!#Q5K
M:4]LM'-7Q]1NK8)T1.B)T1.B)T1.B)T1.B)T1.B)T15A?*-R4J>'Y#7*HZHN
M9ZE>]#LC16L4O5:HQO%.81=961>SURF:T\.F5P,<1=)FQ,!TC`^>D.4PE24*
M.Q]N=L6W<UT8,BP/QC!5]0#4\@-P(J./#^*B?U6]8<KZ28R&][7N'0=V7+BV
M(M>]A;$*=5[C&]CMIT8!N`)=77:0J2Z-S\EZ5<:S:T.,G#ZNC!R[9RZG<YX_
MP=7OT7%K^9E-NZ;8$Y)R,58R0[IP#50R:B1E!`BA#)G.`[H/2WM:V)EL(6MN
MP#M=M8W7E4M8#3QH:TJH!/UC^L^2+;+N#(R3X61P$T9DN'582-U`^=["X?B;
MN:X;@*BBB%IM6DJ;?[1"RLX>UJKO_P`EC;L<QE`OU=N1`M5<OQ%C`'JFN$3+
M)O5@_E)THLB/8R1@#><?.V>RCDC:&-I0M'!KA[)%*Z4(('V5YJMW<UA<8[.7
M$5Q+U][^HV;CUHY?B,EKSZC7!Q\"2#J"M'.:S)6^]5J'BIH:LHV??D\E<P4,
MD%#KM.(:SV.^'5*/=(]1B8M1XA_E5TFDB7ZU2@/*]GCAM']1N\N&T,I^)SO9
M:!R.O'RUX+AVY8SY#,P1V\O0V.ZCIN'19%\1\E1K[#6DCQ=0#4A6@OOF@Y+^
M^>C`T;'0KX/7008V6"N"UD-"%74+%*V%6+NL;&'GEF()G>>V;H-P<&."9"D`
MH!I;/3S'.C#GS3"7;4@;2`>=*BM*<*ZJP<WU1=UQRN9:V5BZV:XAAD$G4<T:
M-+]KPW>1J[:`VM:"BM[^/WF2KR]S";D+6R@(+5J+.'B;O`5TKY"(/'R0KO*K
M8X=K*/I*02C9:/3.@<%%U1(]9KE`0+Y0ZT3N7`NP-Z(F$OM'BK''GX@^8_W5
MC?2+U+;ZD8*2ZNF10YJVEVRQL)V[75,;VAQ)HX5:=3[33R(7-9#S8@-.Y2;=
MQ>DZ-)TJ9S&2E&-&MK^<8R</KP5",I4AI"4*T19M%X*9HA=(@3N&*RCA5=I)
M$<D,!"*`77%+->2T7_.BE0%)VJX6*E6KWF7\F9'BO3:15E&=HNNT:7Z-4"K1
M5'BC!$-F\C:GEH\H(NER(1[5FN[=.4VR2BB>*K*ZM/\`,C;<=_&K7R?XFK9)
MC$]/P-:G=3INV5K7BY1(6N6:P5=D=;K+"J5-Q!5-:8?H-GTO$NIQG&*K%.N8
M&_F<%(I(\==U;[Y3[3.*UAS2+10=6T['KW2WDHC-.:[;,UMLA`G#[HW9L$7S
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MV5R7ONB0T>YE$2,4XT'I5E4Q2*8052JDF[W%NTY-P/&X:TY.ZG,,M&V%N`2:
M!6;9"M7RJ4<];-#BU%RHY>'M`.0<@N!"%0$@D$3`8,\UE4&_,IEUX@-^JNNR
M4D^F:#H-1CJA6A7#_ITF>J(.GDK5VX$^@B=A0>'ED3'[*+*^Z+W$J!`"7?3Z
M\MI+)]B/9N8WEQI[X=H*_9P^X>*HO]3V`RMOW1;=Q2N=)B+F!L3/")\=2YGE
MNKU!XDN_E5/JJA$45%E!$J:1#*'-V$1`I`$1$"AW,(B`>`!XB/4@FM>5?MT_
MU58@*Z#BI<Z#+U',(#)LFT/*H/5M)H5$5<7"1L-TT*J*YV2_33F]US%FI*%/
M0!90:'"S173P[_UUF4E,.&20IIM_(&M6MO=WMS/?V=P8+663V0UC';]HVND]
MH.I4B@I3<`'<U+>7R6%[=L,?V[G<9%D\W:VWQ72S31&#JN,K+4=%[=W2:X.<
M75+9)'QB@91<75;%4]`K&I9MGV40677VXTYN[@7E=M^A6]YH4=195.ZVC(CD
MOE@G0BU+7$Q7W!H9AZ2K]["I,5?4(X*3KG-;7MI<175[<NGM8WZM+&L#-WLA
MYV@`T)H:\&N+N2ZUCE</G<=?83`XR'&9>>WJQT4LTIN&Q'JOMOC/?MWM;O;L
MH7OC$9J'446TU"+)IJIG*HFJ0BA%`'N4Z:A0,4X#_GS%-W#K8N`W#0`5T_@H
MM/"BN-^&/-;Y+[G>=8B9-W#9S3J<XI=I3(D4S2\6.QK-).%@#@KX%&KMV0R:
MJJ?]B)ET$_`CE0!CWU"O+=EG%8O`==N<'CQC;3A]AK3_`(5H?I?P67G[DN^X
MH7NCPL$!AD\)I'T+6?\`2F\GB/9'O*3*&;6ZY!SMU''VQ9'>N,7R)S>UY&P0
M4*1:SOX7C?A,=H&2.EDDU%RQ^Q9K(R4$=(1*0CUTS=&^ILF(1$KQK"%'TNL3
MU9:\W*XH]M&"9C\KNB;/H+^,CW4D[K&6:=QP:9<OH4M"L$GC],F2SFBM7<ZD
M5)1Q&,VSU4Q0]L?L3S4Z^>W(G$=4XG:3A^1Z5GFR:URCHTID.)Y_G%NK]YGK
M7/:*T-`-K0@QK;^249TRDM7JDU+32_HQ\<Q8G447*?TRG%"L$;G>+APXUSD1
MFM.E5%KGS;Q;*'_'=VLNFU%_RZ9.ZKQ2N;]BU,8ZCEX2O6.CVM^!`,?VD0_7
M./T'/TX)PT638&+S?@=R[S"-N\JSI.%7?A?E?&C+=0MCEK$4Z$T;!KG=IQS1
M+-:'ADHJO6#4*[>R2K$[U=`LN^C':1#*.`(0S@G!;CEG:J?R[U_`..W'ZYUR
M]W.AV/2M<TZYTF7:66OXO5'&`Z_E-<1MUDK[AVRA+/?;EI+-"-BC+`_<LVCM
MUZ0(-Q.).*WW&GFCC5#X50=4L%RSW+]\XPX.TSW1<&TZU0M)MM3TG':`G!*P
M[ZO2\A&2KNJV"3@2+Q4FS*HSDXUTDLV6/YO!71*Z*-\?I$/K_*2BZGHO*%YP
M[E]0^-#B?I#]U2;MD%3:SLO>+MK%BDZXU7W"H7<C^(KKI^86PMDTG)2J]UE#
M>8H=$YK.5SIF9;GRLP+*I>_I[QFVC_'7RSS^<OAI^J3C[0X=;3N.%;F[">=H
M\?%U96>!^D=0[F,:-D6DBGYDDTC)E*4BB%%6_DG=-XE,(A9PA^8V/</[KQ3N
M=T<=D'S:-L_)_CY7('E4T9F4]5T62P&U%OR9"E],TPR=,O\`4B8O36JQ_%7J
M[M@V9\D,^>9EJ\*M-U9W)14R0C*0>1$G'RT,Z*Z8R$7+1ZJ+U@Z('G2.9,P>
MHW642-W(<P#Z&-R5WB;MM[9.VSMKYBA\1^VJUONWM+"]ZX9^"ST;GV+WM=[)
MVO:YIJ'-=K0\0=-6DCFH<0OQ.<.ZY-0]CB*M;5)BO2C&<ARSM\L\_"EEXEPF
M^BU96!>R(,9I@W?H)J*-%^Z*X$\AP$@B`[%+WQFYH76\IBZ3FD&C:.H>-'5-
M"1SY*,;/Z>/3O'W<=]:LNC<PO#V=27>S>W5I<R@W-!H2TD!U*'0KS&;53;[G
MNQZC2]4=+R6BPEWGAMTT[`04LDG*O5)HEL2,8>YF=L9R*<@C_@J;@"?[1`)>
MQ,]K=8R&>Q%+8L%`-:4Y'S'#[E13O/%Y?#=U7^.SSB_*LN7F1Y_R%QW"0>3P
M0\>3@M/&J=>]#U[,:3ERRS/0YV[P!:A*MP.(UR4C7J<P>VKBF`B#&J,V"D@O
MW\#)-S$'OYNP\\I<6]ICI9[L@0-8[<#[S2*;!YN/!<.T,7ELUW18X[!5&4DN
M&=-P]PM=NZA_I8`7.\@5Z7Y/XB.(,S)R4R_CM!;OYB1>2\@C"7F2A85.0D7"
MKQ\$1#()JH0\:+I<XHM4S"DW3$$R?24.H;B[VSL+>FQ[#&!0!S0Z@^T\3YJ^
M$_T\>FUU,ZYN(+CYB1Q<[9,YC=SC4[6#1K:DT:-&C0<%-W!<%SCC;G,=EV6Q
MCN.K,>_E)4ZDF_6EIB3E9AV9V_DI>4<=EW[Q3N1(IC``$0233*`%(4`U_(Y&
M[RMT;R]=NF(`X4%!R`_;52?VKVIA.S,0S!X"(Q6+7.=J2YSG.-2YSCJX\!4\
M``.2RJQB8J,5D5HV,CX]:7?&E)95BS;-%923.W;M#R,BH@FF9Z^,T9I)"LJ)
ME!32(7OV*4`Z*V-;.&K-;KC)U&UZO0<%'/GCV1>L(:)81;)Y(21O/(OW35BW
M00</'Y_%94Y1.J/B81Z(NJT_'LCSV5E)V@Y;G-'FYL#A-3%/I%9K,K+@HKZY
MPE)"%C&3N0`Z_P!8^J<_<_C_`#T1=MDJY7IA_#2LO`PTK*5QRN]KTE)1;%\_
M@7CE'VSEW#/'*"KB+<N&_P#6=1`Q#')](B(>'1%\L-;KMNAG]<M<#"V>O2B/
MMY."L,6QFH:1;^8#>@_BY)!RR>(^8H#Y5"&+W#^.B+BJ7GU"S:(&`SJD5"@P
M(KG<C"4NM0U6B!<J``*.!C8-DQ9^N<`#N?R>8>WB/1%PMNQK(-`EF$]?<IS:
M[3L4!"Q<U;J-6+)+1I4S^HF5A(S,6]>,P3/]103.7L/B'1%N+%DN57!5BM;<
MRSZT+1;%&+C5;%3*Y-JQT8W$QD(YBI)QKDS1BB8YA(BF)4RB(]@#OT1<S!TB
MEUA.*2K=0J]>2@F#^*@TX.`B8E.&C)5ZE)2D=%$8-&Y8YA)2*!'#A%$")K+D
M*<X"8`'HBWZ=<KR,\YM*,##)6=Y'I1#NQIQ;$D\ZBFZWN$(QS+E0"07CT5_K
M(B904RG\0*`^/1%S/1$Z(J*/DM_\!?O>N?O[][_M?]>,?N7Z'_&/;_C?W>1_
M&_SC[]]'WKU/=^R\G]WL_P#D_K]#J0NT_P!4?(/_`"GH_)=3_+6FZFNVG[_/
M[U5OUJ_\;_4T/ZW^?_/?E6U^4V_V]SMG5K[W';SV4KIM3XT__`/[WL7Z"_>W
M[6_7SW[9^^/Q?T/QW[JR_(OP?[#]/WOO[;WOG_M]E_Q_U^OUGNO]4?E[?S;H
M?)=4?VZ_BH:5KK3]U:>2QZ+?^-?J>7]$_/\`Y]\L[;\WM_!4;^E3WZ4W<]E:
?:55Z_4>*TJ=$3HB=$3HB=$3HB=$3HB=$3HB=$7__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
